Pulmicort 200 Turbohaler (AstraZeneca UK Ltd) 100 dose

Type Dry powder inhaler (DPI)

Medicine Budesonide 200micrograms/dose

Adult steroid dose Low adult steroid dose
Medium adult steroid dose

Activation mechanism Breath actuated

Dose counter Has dose counter

Price £17.10 / 30 days
(based on 4 puffs / day)

Inhaled corticosteroid information For children and adults, a total of 2 puffs/day gives a low dose of ICS, whilst 4 puffs/day gives a medium dose

Steroid safety card recommendation (for adults) Steroid safety card not always required, but recommended for medium doses

Licences

Adult Asthma Licence
Adolescent Asthma Licence age range not available
Paediatric Asthma Licence 5 years and older

Training material

Pathways

The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.

Prescribing

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Dosing

Bronchial asthma

Type	Age Range	Dose
Maintenance	From 5 years to 6 years	1 actuation - TWICE a DAY - inhalation - using a metered dose device
Maintenance	From 6 years	1 actuation - TWICE a DAY - inhalation - using a metered dose device
Maintenance	From 5 years to 6 years	1 actuation - every EVENING - inhalation - using a metered dose device
Maintenance	From 6 years	1 actuation - every EVENING - inhalation - using a metered dose device
Maintenance	From 5 years to 6 years	2 actuations - TWICE a DAY - inhalation - using a metered dose device
Maintenance	From 6 years	2 actuations - TWICE a DAY - inhalation - using a metered dose device
Maintenance	From 5 years to 6 years	2 actuations - every EVENING - inhalation - using a metered dose device
Maintenance	From 6 years	2 actuations - every EVENING - inhalation - using a metered dose device
Maintenance	From 12 years	3 actuations - TWICE a DAY - inhalation - using a metered dose device
Maintenance	From 12 years	3 actuations - every EVENING - inhalation - using a metered dose device
Maintenance	From 12 years	4 actuations - TWICE a DAY - inhalation - using a metered dose device
Maintenance	From 12 years	4 actuations - every EVENING - inhalation - using a metered dose device

Drug Interactions

With	Risk	Severity
RITONAVIR	Increased risk of systemic corticosteroid adverse effects	High Risk: Avoid combination. Risk outweighs benefits.
(ATAZANAVIR WITH COBICISTAT)	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(INDINAVIR)	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(NELFINAVIR)	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(SAQUINAVIR)	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(TELITHROMYCIN)	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
APALUTAMIDE	exposure may be reduced by	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
BEROTRALSTAT	plasma level may be increased by	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
CLARITHROMYCIN	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
COBICISTAT	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
DARUNAVIR WITH COBICISTAT	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR DISOPROXIL	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
IDELALISIB	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
ITRACONAZOLE	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
KETOCONAZOLE	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
LENACAPAVIR	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
NEFAZODONE	Increased risk of systemic corticosteroid adverse effects	Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.